BG110468A - Treatment of neurotic disorders - Google Patents

Treatment of neurotic disorders Download PDF

Info

Publication number
BG110468A
BG110468A BG11046809A BG11046809A BG110468A BG 110468 A BG110468 A BG 110468A BG 11046809 A BG11046809 A BG 11046809A BG 11046809 A BG11046809 A BG 11046809A BG 110468 A BG110468 A BG 110468A
Authority
BG
Bulgaria
Prior art keywords
test
treatment
disorder
day
disorders
Prior art date
Application number
BG11046809A
Other languages
Bulgarian (bg)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG110468(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BG110468A publication Critical patent/BG110468A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
BG11046809A 1999-07-08 2002-01-04 Treatment of neurotic disorders BG110468A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (fr) 1999-07-08 2000-07-07 Traitement de troubles nevrotiques

Publications (1)

Publication Number Publication Date
BG110468A true BG110468A (en) 2010-01-29

Family

ID=8099796

Family Applications (4)

Application Number Title Priority Date Filing Date
BG106279A BG106279A (bg) 1999-07-08 2002-01-04 Лечение на нервни разстройства
BG11046809A BG110468A (en) 1999-07-08 2002-01-04 Treatment of neurotic disorders
BG11046709A BG110467A (en) 1999-07-08 2002-01-04 Treatment of neurotic disorders
BG11046609A BG110466A (en) 1999-07-08 2002-01-04 Treatment of neurotic disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG106279A BG106279A (bg) 1999-07-08 2002-01-04 Лечение на нервни разстройства

Family Applications After (2)

Application Number Title Priority Date Filing Date
BG11046709A BG110467A (en) 1999-07-08 2002-01-04 Treatment of neurotic disorders
BG11046609A BG110466A (en) 1999-07-08 2002-01-04 Treatment of neurotic disorders

Country Status (38)

Country Link
US (6) US7271194B2 (fr)
EP (4) EP1200081B1 (fr)
JP (1) JP4773011B2 (fr)
KR (1) KR100604176B1 (fr)
CN (1) CN1198610C (fr)
AR (1) AR021155A1 (fr)
AT (1) ATE339955T1 (fr)
AU (6) AU782514B2 (fr)
BG (4) BG106279A (fr)
BR (1) BR0011578A (fr)
CA (4) CA2687394A1 (fr)
CL (3) CL2008003939A1 (fr)
CO (1) CO5190674A1 (fr)
CY (1) CY1105806T1 (fr)
CZ (1) CZ200270A3 (fr)
DE (1) DE60030861T2 (fr)
DK (1) DK1200081T3 (fr)
EA (1) EA006555B1 (fr)
ES (1) ES2272298T3 (fr)
HK (1) HK1048069B (fr)
HR (1) HRP20010820A2 (fr)
HU (1) HUP0201791A3 (fr)
IL (5) IL146131A0 (fr)
IS (1) IS6137A (fr)
ME (2) ME00032B (fr)
MX (1) MXPA01011626A (fr)
MY (1) MY143278A (fr)
NO (4) NO329021B1 (fr)
PL (1) PL352030A1 (fr)
PT (1) PT1200081E (fr)
SI (1) SI1200081T1 (fr)
SK (1) SK82002A3 (fr)
TR (4) TR200402276T2 (fr)
TW (1) TWI232101B (fr)
UA (1) UA77645C2 (fr)
WO (1) WO2001003694A1 (fr)
YU (1) YU78701A (fr)
ZA (1) ZA200108856B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
NZ523720A (en) * 2000-07-21 2004-07-30 H Novel compounds and their use as glycine transport inhibitors
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
EA006213B1 (ru) 2001-07-31 2005-10-27 Х. Лундбекк А/С Кристаллическая композиция, содержащая эсциталопрам
US20040067963A1 (en) * 2002-07-08 2004-04-08 University Of Florida Methods to prevent or ameliorate trauma-related psychological disorders
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
PT1578738E (pt) * 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (fr) * 2003-12-02 2005-06-16 B&B Beheer Nv Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0617382A2 (pt) 2005-10-14 2017-07-11 H Lundbeck As Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (fr) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (fr) 1991-04-16 1992-10-29 National Institutes Of Health Procede de traitement de la trichotillomanie et de l'onychophagie
DK0612242T3 (da) 1991-11-15 2003-10-20 Sepracor Inc Anvendelse af ren S(+)-isomer af fluoxetin til fremstilling af et medikament mod migræne
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (fr) * 1995-02-10 1996-08-15 Eli Lilly And Company Procede de traitement ou de prevention de troubles psychiatriques
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
ES2145977T3 (es) 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
EA002770B1 (ru) * 1997-11-11 2002-08-29 Х.Лундбекк А/С Способ получения циталопрама
ES2188095T3 (es) * 1998-04-15 2003-06-16 Pfizer Prod Inc Carboxamidas heterociclicas.
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
WO2000003701A1 (fr) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition pour le traitement du stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
KR100411505B1 (ko) * 1998-10-20 2003-12-18 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
ATE237604T1 (de) * 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU2001255654B2 (en) 2000-04-24 2005-09-22 Aryx Therapeutics Materials and methods for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
TWI232101B (en) 2005-05-11
TR200402275T2 (tr) 2005-03-21
AU2008264182A1 (en) 2009-01-29
CZ200270A3 (cs) 2002-04-17
EP1440691A2 (fr) 2004-07-28
ZA200108856B (en) 2002-12-24
EP1200081A1 (fr) 2002-05-02
AU5806100A (en) 2001-01-30
NO20100333L (no) 2002-01-07
CN1198610C (zh) 2005-04-27
PT1200081E (pt) 2007-01-31
YU78701A (sh) 2004-03-12
US20020086899A1 (en) 2002-07-04
DE60030861D1 (de) 2006-11-02
BR0011578A (pt) 2002-03-26
AU2005202684B2 (en) 2009-01-15
DE60030861T2 (de) 2007-05-03
TR200402277T2 (tr) 2005-01-24
EA006555B1 (ru) 2006-02-24
MEP2508A (xx) 2010-02-10
TR200402276T2 (tr) 2005-01-24
TR200200014T2 (tr) 2002-05-21
NO20100335L (no) 2002-01-07
AU2005202686B2 (en) 2009-01-15
KR100604176B1 (ko) 2006-07-25
AU2008264188A1 (en) 2009-05-07
EP1200081B1 (fr) 2006-09-20
BG106279A (bg) 2002-08-30
CO5190674A1 (es) 2002-08-29
US7265151B2 (en) 2007-09-04
EP1440690A3 (fr) 2004-08-18
BG110467A (en) 2010-01-29
CA2373757A1 (fr) 2001-01-18
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CA2687394A1 (fr) 2001-01-18
JP2003504332A (ja) 2003-02-04
UA77645C2 (en) 2007-01-15
ATE339955T1 (de) 2006-10-15
US20050101665A1 (en) 2005-05-12
IL146131A0 (en) 2002-07-25
IL170193A (en) 2010-04-29
PL352030A1 (en) 2003-07-28
HK1048069B (zh) 2005-12-16
EP1440690A2 (fr) 2004-07-28
IL146131A (en) 2007-02-11
EA200200137A1 (ru) 2002-06-27
CL2008003938A1 (es) 2009-05-22
NO20100334L (no) 2002-01-07
NO20020062D0 (no) 2002-01-07
AU2005202684A1 (en) 2005-07-14
AU782514B2 (en) 2005-08-04
MY143278A (en) 2011-04-15
EP1440689A3 (fr) 2004-08-25
DK1200081T3 (da) 2006-12-27
US20040029957A1 (en) 2004-02-12
CN1360501A (zh) 2002-07-24
EP1440691A3 (fr) 2004-08-25
US20040029956A1 (en) 2004-02-12
HK1048069A1 (en) 2003-03-21
KR20020015346A (ko) 2002-02-27
NO329021B1 (no) 2010-07-26
CY1105806T1 (el) 2011-02-02
AU2005202686A1 (en) 2005-07-14
ES2272298T3 (es) 2007-05-01
CA2373757C (fr) 2010-01-05
CL2008003939A1 (es) 2009-06-05
WO2001003694A1 (fr) 2001-01-18
MXPA01011626A (es) 2002-06-04
US20070276035A1 (en) 2007-11-29
IL170194A (en) 2010-05-31
EP1440689A2 (fr) 2004-07-28
JP4773011B2 (ja) 2011-09-14
BG110466A (en) 2010-01-29
US7271194B2 (en) 2007-09-18
CL2008003941A1 (es) 2009-05-22
AR021155A1 (es) 2002-06-12
SK82002A3 (en) 2002-07-02
IS6137A (is) 2001-10-30
HUP0201791A2 (en) 2002-10-28
HUP0201791A3 (en) 2005-02-28
US6960613B2 (en) 2005-11-01
AU2005202685B2 (en) 2009-01-15
IL170192A (en) 2010-04-29
HRP20010820A2 (en) 2003-08-31
CA2687396A1 (fr) 2001-01-18
ME00032B (fr) 2010-02-10
CA2687392A1 (fr) 2001-01-18
AU2005202685A1 (en) 2005-07-14
US20040029958A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
AU2005202685B2 (en) Treatment of Neurotic disorders
EA008373B1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA008372B1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой